{"id":22,"date":"2023-07-04T14:56:57","date_gmt":"2023-07-04T13:56:57","guid":{"rendered":"http:\/\/tris.sambrownprojects.com\/?page_id=22"},"modified":"2024-05-29T14:08:58","modified_gmt":"2024-05-29T13:08:58","slug":"adhd-products","status":"publish","type":"page","link":"https:\/\/www.trispharma.com\/adhd-products\/","title":{"rendered":"ADHD Products"},"content":{"rendered":"
[vc_row el_class=”subnav-shortcode” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D”][vc_column][vc_column_text css=”.vc_custom_1692361026548{margin-bottom: 0px !important;}”]
[\/vc_column_text][\/vc_column][\/vc_row][vc_row el_class=”complaince-copy-row” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D”][vc_column][vc_column_text css=”” el_class=”scientific-board-bios”]Our therapies are designed to provide consistent delivery of ADHD medications despite patient-to-patient variability because of the medications’ smooth-release profile. The therapies are available in both oral suspension (liquid) and solid (tablet) forms. View clinical publications<\/a> supporting our ADHD medicines.<\/p>\n The portfolio currently features five FDA-approved ADHD medications for the treatment of individuals six years of age and older.[\/vc_column_text][\/vc_column][\/vc_row][vc_row el_class=”brand-infolist-parent-row amphetamine” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D”][vc_column][vc_column_text css=”.vc_custom_1716970539298{margin-bottom: 15px !important;}” el_class=”darkgreen”]<\/p>\n NEWLY APPROVED<\/span><\/strong><\/p>\n [\/vc_column_text][vc_row_inner][vc_column_inner width=”1\/4″][\/vc_column_inner][vc_column_inner el_class=”liquid-col med-col” width=”1\/2″] Tell your doctor if you, your child or any family members have ever abused or been dependent on alcohol, prescription medicines or street drugs.[\/vc_column_text][\/vc_column][\/vc_row][vc_row full_width=”stretch_row” content_placement=”middle” el_class=”rw-resouces” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D”][vc_column width=”1\/2″][vc_single_image image=”2426″ img_size=”full” alignment=”center” css=”.vc_custom_1714107132527{margin-bottom: 0px !important;}”][\/vc_column][vc_column width=”1\/2″][vc_column_text]<\/p>\n [\/vc_column_text] Our LiquiXR\u00ae<\/sup><\/em> technology allows for medicines that: 1-2<\/a><\/sup><\/span><\/p>\n [\/vc_column_text][vc_video link=”https:\/\/vimeo.com\/846875169?share=copy” align=”center” el_class=”brand-adhd-products-video hideon-desktop”][vc_column_text css=”” el_class=”brand-adhd-products-textblock2″]DYANAVEL and LiquiXR\u00ae<\/sup><\/em> are registered trademarks of Tris Pharma, Inc. Quillivant XR and QuilliChew ER are registered trademarks of NextWave Pharmaceuticals, Inc.<\/p>\n NextWave Pharmaceuticals, Inc. is a wholly owned subsidiary of Tris Pharma, Inc.[\/vc_column_text][\/vc_column][vc_column width=”7\/12″ el_class=”hideon-mobile” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D”][vc_video link=”https:\/\/vimeo.com\/846875169?share=copy” align=”center” el_class=”brand-adhd-products-video”][\/vc_column][\/vc_row][vc_row full_width=”stretch_row” el_class=”brand-callout-row mob-footercallout brand-callout” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D” css=”.vc_custom_1711718171250{margin-bottom: 50px !important;}”][vc_column width=”1\/2″][vc_column_text css=”” el_class=”text-white callout-text text-quote”]<\/p>\n [\/vc_column_text][\/vc_column][vc_column width=”1\/2″][\/vc_column][\/vc_row][vc_row css=”.vc_custom_1700742620230{padding-bottom: 55px !important;}” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D” el_id=”notation” el_class=”rw-notation”][vc_column][vc_column_text css=”.vc_custom_1716867266229{margin-bottom: 0px !important;}” el_class=”notation-typo”]1<\/sup> Pardo A, Kando JC, King TR, Rafla E, Herman BK. Single-dose pharmacokinetics of amphetamine extended-release tablets compared with amphetamine extended-release oral suspension. CNS Spectr. 2020;25(6):774-781. [vc_row el_class=”subnav-shortcode” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D”][vc_column][vc_column_text css=”.vc_custom_1692361026548{margin-bottom: 0px !important;}”][\/vc_column_text][\/vc_column][\/vc_row][vc_row el_class=”subpage-first-row” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D”][vc_column][vc_column_text css=””] We\u2019ve harnessed the power of our LiquiXR\u00ae technology to develop a comprehensive and expanding portfolio of leading ADHD therapies\u200b that enhance patient care and experience for individuals with the disorder.\u200b [\/vc_column_text][\/vc_column][\/vc_row][vc_row el_class=”complaince-copy-row” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D”][vc_column][vc_column_text css=”” el_class=”scientific-board-bios”]Our therapies are designed to provide consistent delivery of ADHD medications despite […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":"","_wp_rev_ctl_limit":""},"class_list":["post-22","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\n
\nImportant Safety Information<\/i><\/a>[\/vc_column_text][vc_column_text css=”” el_class=”brands-color-box onyda-tablet”]Website Coming Soon<\/span><\/a>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/4″][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row el_class=”brand-infolist-parent-row amphetamine” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D”][vc_column][vc_row_inner][vc_column_inner el_class=”med-col” width=”1\/2″]
\nBoxed Warning, Important Safety
\nInformation and Medication Guide<\/i><\/a>[\/vc_column_text][vc_column_text el_class=”brands-color-box amphatamine-tablet”]Visit Website <\/i><\/a>[\/vc_column_text][\/vc_column_inner][vc_column_inner el_class=”liquid-col med-col” width=”1\/2″]
\nBoxed Warning, Important Safety
\nInformation and Medication Guide<\/i><\/a>[\/vc_column_text][vc_column_text el_class=”brands-color-box amphatamine-liquid”]Visit Website <\/i><\/a>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row el_class=”brand-infolist-parent-row methylphenidate” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D”][vc_column][vc_row_inner][vc_column_inner el_class=”med-col” width=”1\/2″]
\nBoxed Warning, Important Safety
\nInformation and Medication Guide<\/i><\/a>[\/vc_column_text][vc_column_text el_class=”brands-color-box methylphenidate-tablet”]Visit Website <\/i><\/a>[\/vc_column_text][\/vc_column_inner][vc_column_inner el_class=”liquid-col med-col” width=”1\/2″]
\nBoxed Warning, Important Safety
\nInformation and Medication Guide<\/i><\/a>[\/vc_column_text][vc_column_text el_class=”brands-color-box methylphenidate-liquid”]Visit Website <\/i><\/a>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row css=”.vc_custom_1712050638422{margin-top: 100px !important;}” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D” el_class=”dynavelXR-para-row”][vc_column][vc_column_text css=””]DYANAVEL XR, Quillivant XR and QuilliChew ER have a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including DYANAVEL XR, Quillivant XR and QuilliChew ER, can result in overdose and death. Before prescribing DYANAVEL XR, Quillivant XR or QuilliChew ER, assess each patient\u2019s risk for abuse, misuse and addiction. Educate patients and their families about these risks, proper storage of the drug and proper disposal of any unused drug. Throughout treatment, reassess each patient\u2019s risk and frequently monitor for signs and symptoms of abuse, misuse and addiction.<\/strong><\/p>\nADHD resources for physicians, caregivers and patients are available.<\/h3>\n
Our ADHD therapies harness LiquiXR\u00ae<\/sup><\/em> technology<\/h3>\n
\n
To learn more about ADHD and our medicines, visit TrisADHD.com<\/a>.<\/h2>\n
\n2<\/sup> Kando JC, King TR, Pardo A. A novel, modified release drug delivery technology containing amphetamine and methylphenidate ion-exchange complexes. Poster presented at American Psychiatric Association Annual Meeting; May 1-3, 2021.[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"